SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022699
Filing Date
2022-11-07
Accepted
2022-11-07 17:02:46
Documents
62
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20220930.htm   iXBRL 10-Q 2862684
2 EX-31.1 avir-ex31_1.htm EX-31.1 18644
3 EX-31.2 avir-ex31_2.htm EX-31.2 18947
4 EX-32.1 avir-ex32_1.htm EX-32.1 13278
5 EX-32.2 avir-ex32_2.htm EX-32.2 12396
  Complete submission text file 0000950170-22-022699.txt   7590678

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avir-20220930_pre.xml EX-101.PRE 228972
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avir-20220930_def.xml EX-101.DEF 117321
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avir-20220930_cal.xml EX-101.CAL 39962
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avir-20220930.xsd EX-101.SCH 38777
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avir-20220930_lab.xml EX-101.LAB 323957
56 EXTRACTED XBRL INSTANCE DOCUMENT avir-20220930_htm.xml XML 1165081
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 221366295
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences